INTRODUCTION
ly, and each process is characterized by the expression specific proteins, including occludin, claudins, keratins, transglutaminases (TGs), loricrin, and FLG. 22, 23, 26, 27 Keratinocytes express specific differentiation markers according to their stage of epidermal differentiation. 22 For instance, keratin 5 and TG2, which are expressed in the basal layer, represent early differentiation markers. In contrast, FLG, which is expressed in the upper granular and cornified layers, is a late differentiation marker. Tight junctions (TJs), desmosomes, and adherens junctions are paracellular proteins that form a permeability barrier between adjacent cells and involve cell adhesion. [26] [27] [28] [29] Keratinocytes also produce AMPs including cathelicidin (LL-37) and beta-defensins (HBDs), which kill microbes and play important roles in maintaining skin homeostasis. 30, 31 In addition to their antibacterial activity, AMPs kill viruses and fungi through multiple modes of action. 31 The levels of AMPs, such as HBDs and LL-37 in epidermis, are low in normal health conditions, but are highly expressed upon infection and inflammation. 31, 32 AMPs form an innate epithelial chemical barrier and have pleiotropic functions. 31, 33 They not only kill microbes, but also control inflammation and regulate the skin barrier. 31, 34, 35 Impaired TJ protein expression contributes to skin barrier dysfunction in AD. 36 HBD-3 improves the function of the epithelial TJ barrier by inducing expression of several claudins. 34 HBDs and LL-37 also induce production of IL-18 through p38 and Erk mitogen-activated protein kinase activation in human keratinocytes. 37 Additionally, they induce expression of IL-6, IL-10, macrophage inflammatory protein-3 alpha, and RANTES. 38 Furthermore, it has been reported that HBDs and LL-37 induce keratinocyte migration, proliferation, re-epithelialization, neovascularization, and wound healing. 31, 35, 38, 39 The cornified layer is surrounded by a continuous lipid matrix which provides a barrier against water and prevent water loss. 24, 40, 41 The lipid matrix mainly consists of 3 lipid classes: cholesterol, free fatty acids, and ceramides. 23, 42 Therefore, the lipid matrix in the cornified layer may play crucial roles as a part of skin barrier and shows altered composition in AD skin.
It has also recently been reported that the epidermal microbiome may also play crucial roles in maintaining skin barrier function. 4, 16, 43 Previously, the biogeography of the skin microbiome has been reported in children and adults. 44, 45 Several studies have shown that human skin microbiome is site-specific. [44] [45] [46] Recently, it has been reported that the gut and cutaneous commensal bacteria, including Staphylococcus (S.) epidermidis, and S. hominis, play important roles in skin homeostasis and host defense against microbial penetration.
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Dysregulation of the skin barrier in AD
Epidermal barrier proteins, including FLG, TGs, keratins, loricrin and intercellular proteins, are cross-linked to form an impermeable skin barrier. 22, 23 Skin barrier defects facilitate allergen sensitization and lead to systemic allergic responses, such as increased IgE levels and airway hyperreactivity. 36, [51] [52] [53] Transepidermal water loss (TEWL) is a noninvasive measurement used to evaluate skin barrier function. 54 Patients with AD have increased TEWL, which reflects skin barrier dysfunction in AD, and can precede clinical AD. 55, 56 AD skin is characterized by overexpression of Th2 and Th22 cytokines that contribute to skin barrier dysfunction by altering protein and lipid content in the skin (Table 1) . 2, 4, 57, 58 FLG is a key epidermal barrier protein. 22, 59 It is degraded into free amino acids and these amino acids are essential for maintaining skin pH and the retention of water contributing to osmolarity in the cornified layer. [60] [61] [62] FLG deficiency alters the shape of corneocytes in the skin and enhances skin inflammation by facilitating epicutaneous sensitization in murine models of eczema. 41, 63 FLG deficiency also causes paracellular skin barrier abnormality that reduces inflammatory thresholds to irritants and haptens. 41, 64 FLG proteolysis occurs upon exposure to a low humidity environment and can be prevented by high humidity. 65 FLG is decreased in AD skin by overexpression of IL-4, IL-13, IL-25, IL-17A, and IL-22 ( Fig. 2) . 57, 59, 66, 67 Additionally, loricrin, and involucrin, which are major epidermal barrier proteins, are also down-regulated by Th2 cytokines through STAT6 signaling in AD skin. 68 It is well known that FLG mutation is a major predisposing factor for AD development, particularly in patients who have early-onset AD and those with persistent AD. 21, 55, [69] [70] [71] [72] However, a significant number of AD patients do not have any type of FLG gene mutation, and about 40% of individuals with FLGnull alleles do not have AD. 21, 73 Moreover, most of the patients with AD and FLG mutations eventually recover from AD. 21, 73, 74 Therefore, FLG mutations contribute to AD, but in isolation it is not sufficient to generate AD. There are other factors that result in AD development. Intercellular proteins, including TJs, desmosomes, and adherens junctions, form a permeability barrier between adjacent cells and aids with cell adhesion. [26] [27] [28] [29] Th2 cytokines down-regulate TJs, and impaired TJs contribute to abnormal skin barrier function in AD. 36, 75 Corneodesmosin (CDSN) is an intercellular protein that plays a critical role in maintaining skin barrier function. 29, 76 Recently, Lee et al. 77 have reported that CDSN expression is down-regulated by cytokines, including IL-4, IL-13, IL-22, IL-25, and IL-31. Additionally, CDSN deficiency resulted in lethal-skin barrier disruption in a mouse model, 76 and enhanced viral penetration in an organotypic skin model. 77 Therefore, a variety of cytokines modulate epidermal barrier proteins, and cause skin barrier defects.
AMPs, such as LL-37 and HBD-3, are highly expressed by keratinocytes during infection, inflammation, and wounding. 30, 31 AMPs form an innate multidimensional epithelial chemical barrier. 31, 33 They not only have antimicrobial activities, but also Staphylococcal infection, dry skin, and increased TEWL.
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Recurrent microbial infections, skin dysbiosis, and exacerbation of AD. regulate the skin barrier. 31, 34, 35 AMP expressions are inhibited in AD skin by Th2 cytokines, which are overexpressed in AD skin. 32, [78] [79] [80] The deficiency of AMPs and over-expressed Th2 cytokines in AD skin is associated with a higher propensity to S. aureus infection, which is known to play critical roles in the exacerbation of AD. 30, 31, 81 Son et al. 82 have reported that S. aureus inhibited expression of terminal differentiation markers, including FLG, loricrin, and keratina 1 and 10. Recently, Brauweiler et al. 83 have also demonstrated that S. aureus lipoteichoic acid inhibits keratinocyte differentiation markers, including keratins 1 and 10, and desmocollin1, through a p63-mediated pathway. Therefore, deficiency of AMPs and overexpressed Th2 cytokines in AD skin may lead to frequent microbial skin infections and skin barrier defects. 32, 84, 85 AD skin also has a defective lipid matrix. This causes impaired skin barrier function. 18, 86, 87 Stratum corneum intercellular lipid composition in AD skin is characterized by altered expression of enzymes involved in the biosynthesis of free fatty acids and ceramides. 86, 88 Researchers have demonstrated that altered composition of stratum corneum intercellular lipids correlates with S. aureus colonization status in AD. 89 Additionally, it has been reported that a synthetic omega-hydroxyceramides enhanced the integrity of the stratum corneum, and accelerated the recovery of damaged skin barrier function by stimulating differentiation processes. 90 Lowe et al. 91 also reported that routine lipid replacement reduced the incidence of AD during the active treatment period by approximately fifty percent. Therefore, the lipid matrix in the cornified layer may play a crucial role as part of the skin barrier.
Microbiome AD is associated with abnormal skin colonization of pathogens, such as S. aureus. 4, 92 Commensal bacteria induce AMPs and inhibit S. aureus on the human skin. 16 In contrast, cutaneous dysbiosis affects skin immune responses and causes skin inflammation. 49, 93, 94 Moreover, skin dysbiosis may cause skin barrier defects. 95, 96 Species-level investigation of AD flares demonstrated greater S. aureus predominance in patients with more severe disease, and S. epidermidis predominates in patients with less severe disease. 49 Additionally, S. aureus isolates from AD patients with more severe flares induced epidermal thickening and expansion of cutaneous Th2 and Th17 cells. 49 However, Kennedy et al. 97 reported that commensal staphylococci were significantly less abundant in infants with AD. This finding suggests that commensal bacteria might protect against the development of AD.
AMPs, such as HBD-3 and LL-37, are highly expressed after various exposures in the normal healthy skin. 31 Down-regulated AMPs by Th2 cytokines in AD skin causes recurrent microbial infections and may affect skin pH. 41, 85, 98 Several factors, including FLG, cytokines, proteases, enzymes, and microbes, alter skin pH. 42, 98, 99 Skin pH is an important factor controlling skin homeostasis. Increased skin pH also facilitates microbial skin infections and skin barrier defects. 4, 98, 99 Additionally, Brauweiler et al. 100 have demonstrated that staphylococcal alpha toxin, a primary toxin of S. aureus, causes cell death and consequently skin barrier defects. Thus, decreased levels of AMPs may cause skin dysbiosis and skin barrier defects. In summary, the skin dysbiosis and deficiency of AMPs may affect skin homeostasis and cause skin barrier defects in AD skin. 4, 16, 47, 49 However, additional studies are needed to elucidate how dysbiosis affects epidermal barrier function.
Clinical implications in the treatment of AD
Moisturizers, including petrolatum, physiological lipid mixtures, and ceramide-dominant triple-physiolosic lipid (ceramide: cholesterol:free fatty acids at a 3:1:1 molar ratio), play critical roles in AD management. 1, 101, 102 They improve clinical symptoms and skin barrier function, and reduces bacterial colonization. 4, [102] [103] [104] [105] [106] [107] Petrolatum improves skin barrier functions by upregulation of AMPs, including LL-37, HBD-2, elafin, and S100 proteins. 101 Additionally, epidermal differentiation markers, such as FLG and loricrin, are induced by moisturizers. 4, 101 Moreover, petrolatum significantly reduces T-cell and dendritic cell infiltration in AD skin. 101 Glatz et al. 108 have reported that early emollient therapy alters the skin barrier and microbes in high-risk newborns. Of note, Nakatsuji et al. 16 have demonstrated that application of coagulase-negative Staphylococcus strains to the skin of patients with AD decreases colonization by S. aureus.
It has been reported that use of dilute bleach (sodium hypochlorite) baths and intranasal mupirocin treatment improves AD symptoms. 109 Other investigators have reported that topical use of bleach inhibites S. aureus and show beneficial effects on AD skin possibly through intrinsic anti-inflammatory effects. 110, 111 Hyung et al. 112 reported Lactobacillus strain, CJLP55, isolated from kimchi, reduced infiltration of mast cells, eosinophils, and production of Th2 cytokines in AD-induced mouse skin. Additionally, Notay et al. 113 analyzed 315 articles and reported that probiotics and prebiotics improved AD symptoms including quality of life and clinical severity.
Recently, various types of immune therapy have been developed (Table 2 ). Clinical studies with broad and targeted therapies have been applied for patients with moderate-to-severe AD.
1 Cyclosporine and oral glucocorticoids have been used, but there are limitations due to multiple adverse reactions. Dupilumab, anti-IL-4 Rα monoclonal antibody, improved clinical findings in adults with moderate-to-severe atopic dermatitis, without significant safety concerns. [114] [115] [116] [117] Additionally, dupilumab up-regulated genes involved in skin barrier function. 117 It will be interesting to learn if early treatment of AD with dupilumab could prevent progression of the atopic march. 
The Significance of Skin Barrier Dysfunction
Prevention of AD development
Recent studies have demonstrated that moisturizers reduce rates of AD development 4, 104, 105 and that probiotic supplementation may prevent AD. 118, 119 Additionally, investigators have reported that skin commensal bacteria, including S. epidermidis and S. hominis, play crucial roles in skin homeostasis and defense against microbial penetration. [47] [48] [49] It has also been suggested that colonization by commensal staphylococci can modulate skin immunity and might prevent development of AD. 16, 97 Therefore, correcting dysbiosis in AD skin may improve skin barrier function and prevent AD development. Recently, Kelleher et al. 120 have demonstrated that increased TEWL at 2 days and 2 months predates and predicts AD at 1 year. Kim et al. 121 have also reported that thymic stromal lymphopoietin (TSLP) predicts the development of AD during infancy. These data suggest that detection of increased TEWL, TSLP, and skin dysbiosis in early life might predict AD and facilitate introduction of strategies to prevent AD development. These would include early use of moisturizers, topical anti-inflammatory agents, probiotics as well as correction of microbial dysbiosis.
CONCLUSIONS AND FUTURE DIRECTIONS
Factors, including immune dysregulation, epidermal gene mutations, deficiency of AMPs, and skin dysbiosis, may interact with each other and cause skin barrier defects. Several strategies have been utilized to improve skin barrier function and to control AD. Recently, moisturizers, probiotics, and targeted microbiome therapy have been suggested to prevent AD development in early life. Additionally, broad-spectrum and targeted therapies have been considered to control AD and prevent the atopic march in patients with moderate-to-severe AD. Further studies are warranted to determine the efficacy of these diverse strategies, including emollients, probiotics, and commensal bacteria, to prevent development of AD. It is noteworthy that recent data suggests AD is not just a local skin disease, but a systemic immune disease because nonlesional skin and blood profile show inflammatory findings. Therefore, we may need to expand our scope of management, in the future, to systemic treatment in patients with moderate-to-severe AD.
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